https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=11406

Dolutegravir

Magnesium (hydroxide)

A spacing between the drugs is required.

No pharmaceutical opinion available for this interaction.

Mechanism

Cations by chelation may reduce the absorption of Dolutegravir.

Dolutegravir

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Tivicay, Triumeq or Dovato : administer 2 hours before or 6 hours after the antacid.

Juluca : Administer 4 hours before or 6 hours after the antacid.

Monitor for clinical efficacy.

Alternative solution(s)

–

Magnesium (hydroxide)

Pharmacodynamic effects

–

Recommendations

Avoid association, if possible.

Alternative solution(s)

For Tivicay, Triumeq or Dovato : H2 receptor antagonists or proton pump inhibitors. For Juluca : H2 receptor antagonists administered 4 hours or 12 hours after Juluca. Proton Pump Inhibitors contraindicated.

Monitor

–

Tests

Dolutegravir plasma level

CD4+

Viral load HIV

Pharmacokinetic parameters

–

Comment

For more details, see antiacids + dolutegravir.

Comment
Reference
  • 2868
    Dolutegravir (Tivicay), ViiV Soins de santé ULC, Quebec, Canada, 31 janv. 2020.
  • 2858
    Dolutegravir (Tivicay), US Prescribing Information, ViiV Healthcare, August 2013.
  • 3120
    Dolutégravir/abacavir/lamivudine (Triumeq), ViiV Soins de santé ULC, Québec, Canada, 22 nov. 2021.
  • 3441
    Dolutegravir/Rilpivirine (Juluca), ViiV Soins de santé ULC, Quebec, Canada, 5 juillet 2023.
  • 3497
    Dolutegravir/Lamivudine (Dovato), ViiV Soins de santé ULC, Québec, Canada, 27 juin 2023.